News|Articles|September 18, 2026

What CRISPR Gene Therapy Means for HAE: FAQ on This 1-Time Treatment

Fact checked by: Tim Smith

What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.

On September 8, 2026, the US Food & Drug Administration (FDA) accepted Intellia Therapeutics' Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) and granted it Priority Review for hereditary angioedema (HAE), setting a target action date of March 10, 2027.¹

Related to this article